Table 1.

Patient Demographics^a

	N	Females	HTN	CVD	Weight (pounds)	Height (inches)	Age (years)
Totals	184	142	99	47	150.6	63.6	57.5
Midodrine (− +)	86	64	52	19	153.1	63.8	60.7
Midodrine (+ −)	37	33	15	10	145.1	63.1	52.4
Midodrine (+ +)	61	45	32	18	153.4	63.9	59/3

^aThe patient population is also sorted by gender and disease state. For the latter, of these 184 patients with type 2 diabetes, 99 were also diagnosed with hypertension (HTN) and 47 were also diagnosed with a cardiovascular disease (CVD). For row headers with midodrine, plus and minus symbols indicate the presence (“+”) or absence (“−”) of the α₁-agonist in the two consecutive tests being compared. For example, “midodrine (+ −)” indicates that this subpopulation of patients had midodrine on board (“+”) during the first of two consecutive tests (test N) for which a 5-minute seated to a 5-minute standing postural change was performed. Then midodrine was discontinued (“−”) and approximately 3 months later another seated-to-standing postural change was performed in a second of two consecutive tests (test N + 1). See text for details. Patients with diabetes, without SW, and not on an α₁-agonist during this study, “midodrine (− −)” patients, had no abnormal changes in BP or HR with postural change and were not included in this study population, as they did not have more than two serial ANS tests over the time of the study.